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IMPORTANCE There are no disease-modifying treatments for Alzheimer disease (AD), the
most common cause of dementia. Minocycline is anti-inflammatory, protects against the toxic
effects of β-amyloid in vitro and in animal models of AD, and is a credible repurposed
treatment candidate.
OBJECTIVE To determine whether 24months of minocycline treatment canmodify cognitive
and functional decline in patients with mild AD.
DESIGN, SETTING, AND PARTICIPANTS Participants were recruited into a double-blind
randomized clinical trial fromMay 23, 2014, to April 14, 2016, with 24months of treatment
and follow-up. This multicenter study in England and Scotland involved 32 National Health
Service memory clinics within secondary specialist services for people with dementia. From
886 screened patients, 554 patients with a diagnosis of mild AD (StandardisedMini-Mental
State Examination [sMMSE] score24) were randomized.
INTERVENTIONS Participants were randomly allocated 1:1:1 in a semifactorial design to receive
minocycline (400mg/d or 200mg/d) or placebo for 24months.
MAIN OUTCOMES ANDMEASURES Primary outcomemeasures were decrease in sMMSE score
and Bristol Activities of Daily Living Scale (BADLS), analyzed by intention-to-treat
repeated-measures regression.
RESULTS Of 544 eligible participants (241women and 303men), themean (SD) agewas 74.3
(8.2) years, and themean (SD) sMMSE scorewas 26.4 (1.9). Fewer participants completed
400-mgminocycline hydrochloride treatment (28.8% [53 of 184]) than 200-mgminocycline
treatment (61.9% [112 of 181]) or placebo (63.7% [114 of 179]; P < .001),mainly because of
gastrointestinal symptoms (42 in the 400-mg group, 15 in the 200-mg group, and 10 in the
placebo group; P < .001), dermatologic adverse effects (10 in the 400-mg group, 5 in the
200-mg group, and 1 in the placebo group; P = .02), and dizziness (14 in the 400-mg group, 3 in
the 200-mg group, and 1 in the placebo group; P = .01). Assessment rateswere lower in the
400-mg group: 68.4% (119 of 174 expected) for sMMSE at 24months comparedwith 81.8%
(144 of 176) for the 200-mg group and83.8% (140of 167) for the placebo group. Decrease in
sMMSE scores over 24months in the combinedminocycline groupwas similar to that in the
placebo group (4.1 vs 4.3 points). The combinedminocycline group hadmean sMMSE scores0.1
points higher than the placebo group (95%CI, −1.1 to 1.2; P = .90). The decrease inmean sMMSE
scoreswas less in the 400-mg group than in the 200-mg group (3.3 vs 4.7 points; treatment
effect = 1.2; 95%CI, −0.1 to 2.5; P = .08).Worsening of BADLS scores over 24monthswas similar
in all groups: 5.7 in the 400-mg group, 6.6 in the 200-mg group, and6.2 in the placebo groups
(treatment effect forminocycline vs placebo = –0.53; 95%CI, −2.4 to 1.3; P = .57; treatment
effect for 400mgvs 200mgofminocycline = –0.31; 95%CI, −0.2 to 1.8; P = .77). Resultswere
similar in different patient subgroups and in sensitivity analyses adjusting formissing data.
CONCLUSIONS AND RELEVANCEMinocycline did not delay the progress of cognitive or
functional impairment in people with mild AD during a 2-year period. This study also found
that 400mg of minocycline is poorly tolerated in this population.
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A lzheimer disease (AD) affects 50 million peopleworldwide,1withnumbersprojected to reach135.5mil-lionby2050; associated costs for theUnited States are
$1.2 trillion.2At the2013DementiaSummit,G8ministers com-
mitted to identifying a cure or disease-modifying therapy by
2025,2 but no therapy has so far been shown to delay the pro-
gressionof cognitive and functional disability. Failureof treat-
ment approaches directed at preventing buildup of β-amy-
loid (Aβ) or tau has stimulated investigation of alternative
treatment approaches, including targeting inflammation.
Alzheimerdisease is associatedwith immune-related and
inflammatory genes, including myeloid-specific sialic acid
binding receptor (CD33), triggering receptor expressedonmy-
eloid cell 2 (TREM2), complement receptor 1 (CR1), andbridg-
ing integrator 1 (BIN1).3Microglial activation is increased inAD.4
Aβ is a proinflammatory agent in AD,5 andmicroglial surface
receptors are also Aβ receptors.6 In early AD, microglia clear
AβbyphagocytosisandproduceAβ-degradingenzymes.7How-
ever, as ADprogresses, accumulation of Aβ stimulatesmicro-
glial production of proinflammatory agents that are associ-
ated with neurodegeneration.7
Two systematic reviews, basedonexpert opinion and tol-
erability,brainpenetration,andpreclinical andearlyphase trial
data on repositioneddrugs identifiedminocyclinehydrochlo-
ride among thehigh-prioritydrugs toprogress to clinical trials
inAD.8,9Minocycline is ananti-inflammatory tetracycline that
crosses the blood-brain barrier and inhibits proinflammatory
microglia. In vitro, minocycline protects against Aβ-induced
cell death and prevents fibrillization of Aβ.10 In transgenic
mice, minocycline prevents Aβ deposition and neuronal
death11; reduces tau phosphorylation and insoluble tau
aggregates12; downregulates inducible nitric oxide synthe-
tase, cyclooxygenase-2, and Aβ precursor protein cleaving
enzyme-113; and protects hippocampal neurogenesis in the
presence of Aβ.14Minocycline reduces interleukin and tumor
necrosis factor levels inmice15 and neuronal death and learn-
ing deficits in rats after Aβ administration.16
We investigatedwhetherminocycline slows thedecline in
cognitive and functional ability in peoplewithmild ADover a
2-year treatment period and whether giving minocycline hy-
drochloride at a higher (400-mg) dose than the 200mg used
in standard practice enhanced efficacy.
Methods
Study Design
The Minocycline in Alzheimer Disease Efficacy (MADE) trial
is a double-blind randomized clinical trial of individualswith
mildADthat is investigatingwhether 200mgor400mgofmi-
nocycline hydrochloride per day slows the rate of decline in
cognitiveandfunctionalabilityover2yearscomparedwithpla-
cebo. Participants were enrolled from National Health Ser-
vicememory services fromMay23, 2014, toApril 14, 2016.Eli-
gible participantshadadiagnosis of possible or probableAD,17
were older than 50 years, could give informed consent for
involvement, had a StandardisedMini-Mental StateExamina-
tion (sMMSE)18 score of 24 to 30, and had a caregiver to su-
pervisemedicationandcompleteBristolActivitiesofDailyLiv-
ing Scale (BADLS) assessments.19 Exclusions included
tetracycline allergy, women of childbearing age, uncon-
trolled serious concomitant illness, stage 3b to 5 chronic kid-
neydisease,moderate liver disease, systemic lupus erythem-
atosus, andparticipation inanotherclinical trial in theprevious
28days.TheMADEtrialwas conducted inaccordancewith the
InternationalConferenceonHarmonizationGoodClinicalPrac-
tice guidelines and theDeclarationofHelsinki.20 Patients pro-
vided written informed consent. The study protocol, patient
andcaregiver informationsheets, and informedconsent forms
were approved by East of England/Essex Research Ethics
Committee and theMedicines andHealthcare ProductsRegu-
latory Agency (trial protocol in Supplement 1). This study fol-
lowed the Consolidated Standards of Reporting Trials
(CONSORT) reporting guideline.
Randomization andMasking
Participants were centrally randomized to receive minocy-
clinehydrochloride, 400mg;minocyclinehydrochloride, 200
mg; or placebo. The minimized randomization procedure
aimed to balance treatment allocation overall and by 4 strati-
fication variables: center, duration of symptoms prior to ran-
domization (<6 months or ≥6 months), sMMSE score (24-26
or 27-30), and age (<65 years, 65-74 years, or ≥75 years). Par-
ticipants were enrolled by their clinicians, or appropriately
trained clinical study officers, who also administered out-
come assessments.
Trial Procedures
Modified-release capsules, containing 100 mg of minocy-
cline hydrochloride, and identically appearing placebo cap-
sules (Modepharma) in foil blister packs, dispensed every 13
weeks, were used. Trial group dosing was as follows: (1) mi-
nocyclinehydrochloride, 400mg (two 100-mgcapsules in the
morningand theevening); (2)minocyclinehydrochloride, 200
mg (one 100-mg capsule plus 1 placebo capsule in the morn-
ing and the evening); and (3) placebo (2 placebo capsules in
the morning and the evening). Participants, carergivers, pre-
scribing clinicians, outcomeassessors, and all trial staffmem-
bers (except statisticians) weremasked to group assignment.
Participants visited the clinic at baseline, week 2, and
months 3, 6, 9, 12, 15, 18, 21, and 24. Information on ad-
herence was collected at each assessment and through dis-
pensing records. Adverse events were recorded at each visit.
Key Points
Question Can 2 years of minocycline treatment modify the course
of mild Alzheimer disease?
Findings In this randomized clinical trial that included 544
participants, 24months of minocycline treatment did not
significantly delay progression of functional and cognitive
impairment compared with placebo.
Meaning Minocycline is not a candidate for disease modification
for patients with symptomatic Alzheimer disease.
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Outcome assessments were at baseline and months 6, 12, 18,
and 24.
OutcomeMeasures
Co-primaryoutcomeswere rate of decline frombaseline to 24
months on sMMSE (scores range from 0 to 30, with higher
scores indicatingbettercognitive function)21 andBADLS(scores
range from 0 to 60, with higher scores indicating greater
impairment).22 Secondary outcomeswere safety and concur-
rent infections.
Statistical Analysis
Predefined primary analyses were of minocycline (any dose)
vs placebo and of minocycline hydrochloride 400mg vs 200
mg. Based on previous studies, we estimated that 24-month
assessments would be available for at least 80% of surviving
participants (approximately 390 participants), which would
provide 90% power at P < .05 to detect a small to moderate
(0.35SD) effect size forminocycline (anydose) comparedwith
placeboon theprimary outcomemeasures.With outcomeas-
sessments on 130 patients allocated minocycline hydrochlo-
ride, 400 mg, and 130 allocated minocycline hydrochloride,
200mg,wewouldhave80%poweratP < .05todetecta0.35-SD
treatment effect of 400 mg compared with 200 mg at 24
months.
Only participantswho received at least 1 capsule of study
treatment were to be included in the analyses of primary and
secondaryoutcomes.Theprimaryanalysesof theeffect ofmi-
nocycline on the rate of decline of sMMSE and BADLS scores
and subgroup analyses used intention-to-treat repeated-
measures regression methods, adjusted for baseline scores.
These analyses use all available assessment data tomaximize
statistical power to detect any differences between treat-
mentsand tominimize theeffectofmissingoutcomedata.Dif-
ference in the rate of decline betweenminocycline (any dose)
andplacebo, andbetweenpatients allocated400mgand200
mgofminocyclinehydrochloride,was comparedusinga time-
by-treatment interaction test, with time modeled as a con-
tinuous variable. Comparisons of time prescribed trial medi-
cation over the 24-month follow-up period split by treatment
groups are displayed in Kaplan-Meier curves, with statistical
significance determined by log-rank tests. Reasons for stop-
ping trialmedicationandadverseeventsare tabulatedby treat-
ment group. We used SAS, version 9.3, software (SAS Insti-
tute) for statisticalanalyses.AllPvalueswere from2-sidedtests
andresultsweredeemedstatistically significantatP < .05.The
trial is registered with the International Standard Random-
izedClinicalTrialsNumber register (ISRCTN16105064)and the
European Union Clinical Trials Register (EudraCT 2013-
000397-30).
Results
Between May 23, 2014, and April 14, 2016, a total of 886 pa-
tients were screened for eligibility, from whom 554 partici-
pants entered the trial, from 32 National Health Service
memory services in England and Scotland. The reasons for
screening failures are given in eTable 2 in Supplement 2. Ten
patients did not start trial medication and, as prespecified in
the protocol, were excluded from all analyses (Figure 1). The
baseline characteristics of the 544 eligible participants were
well balanced across treatment groups (Table 1).We obtained
sMMSE assessments for 542 of the 544 participants (99.6%)
at baseline, 498 of 544 participants (91.5%) at 6 months, 453
of 537 participants (84.4%) at 12 months, 420 of 528 partici-
pants (79.5%)at 18months, and403of517participants (77.9%)
at 24 months (eTable 1 in Supplement 2).
Minocycline hydrochloride, 400 mg, was poorly toler-
ated,with28.8%ofparticipants (53of 184) completing2years
of treatment, significantly fewer than in the 200-mg group
(61.9% [112 of 181]) or the placebo group (63.7% [114 of 179];
P < .001) (Figure 1 and Figure 2). Minocycline hydrochloride,
200mg,waswell tolerated,with similar discontinuation rates
withplacebo.Themeandurationof treatmentwas 11.4months
in the 400-mg group, 18.6 months in the 200-mg group, and
18.9months in the placebo group.When reasons for stopping
trial treatmentwere compared (Table 2),moreparticipants al-
located to minocycline than to placebo stopped because of
gastrointestinal symptoms (42 in the 400-mg group, 15 in the
200-mg group, and 10 in the placebo group; P < .001), der-
matologic adverse effects (10 in the 400-mg group, 5 in the
200-mg group, and 1 in the placebo group; P = .02), and
dizziness (14 in the 400-mg group, 3 in the 200-mg group,
and 1 in the placebo group; P = .01). Discontinuation rates
did not differ by age, sex, or duration of symptoms (eTable 4
in Supplement 2).
Becauseof thehigher treatmentwithdrawal rate, feweras-
sessmentswereobtained for the400-mgtreatmentgroupthan
for the 200-mg and placebo groups (eTable 1 in Supple-
ment 2). At 24 months, 68.4% (119 received out of 174 ex-
pected) of patients in the 400-mggroup, 81.8% (144 of 176) of
patients in the 200-mg group, and 83.8% (140 of 167) of pa-
tients in the placebo group provided sMMSE assessments.
Change from baseline in sMMSE over time is shown in
Figure 3A. There was a mean 4.1-point reduction in the com-
binedminocycline groups over 24months comparedwith4.3
points in theplacebogroup.The combinedminocycline group
had a mean sMMSE score 0.1 points higher than the placebo
group (95% CI, −1.1 to 1.2; P = .90). The decrease in mean
sMMSE scores over 24 months was less in the 400-mg group
than in the 200-mg group (3.3 vs 4.7 points), but this differ-
ence was not significant (treatment effect = 1.2; 95% CI, −0.1
to 2.5; P = .08).
WorseningofBADLS scores over 24monthswas similar in
all groups: 5.7 in the 400-mg group, 6.6 in the 200-mg group,
and 6.2 in the placebo group, with no significant differences
between participants receiving minocycline compared with
those in the placebo group (treatment effect = −0.53; 95%CI,
−2.4 to 1.3; P = .57) or between those allocated 400 mg and
those allocated 200 mg of minocycline (treatment ef-
fect = −0.31; 95% CI, −0.2 to 1.8; P = .77) (Figure 3B).
Participants in the 400-mg group who stopped treat-
ment were similar to those in other groups, although they
tended to be older (eTable 4 in Supplement 2). To assess how
the higher number of missing outcome assessments in the
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400-mggroup than in the200-mgorplacebogroups (eTable 1
in Supplement 2)might have affected outcome comparisons,
weperformedsensitivity analyses to investigatepotential bias
fromnonrandomwithdrawal. Therewere41participantswho
had a baseline sMMSE assessment but no further assess-
ments, so they did not contribute any information to the pri-
mary analysis (eFigure 1 in Supplement 2). Thosewhodiscon-
tinue treatment in AD trials are often atypical, usually having
worse cognitive and functional ability than those who con-
tinue treatment.21 This finding is evident from the scores of
the 41 participantswith a 6-month sMMSEassessment but no
later assessments. The mean decrease in sMMSE score from
baseline to6months in this subsetwas 3.9points, a rate of de-
crease 3 timeshigher than the 1.3-pointmeandecrease among
the 498 patients who had a 6-month sMMSE assessment and
completed later assessments. It seems likely, therefore, that
patients with no postbaseline assessments, who do not con-
tribute to the estimate of the rate of decline, also had worse
than average decline in cognitive and functional ability.
Toestimatewhateffect themissingoutcomedata fromthe
41 participants with no postbaseline assessmentsmight have
had on the trial results, our sensitivity analyses made 2 dif-
ferent assumptions. Inmethod 1,weassumed that, for the first
6months, theydeclinedata rateof3.9points (asdid thosewho
had a 6-month sMMSE assessment but no further assess-
ments) and then declined at themean rate of 1.1 points every
6 months for the rest of the trial. Method 2 assumed that pa-
tientswithnopostbaseline assessments declined at themean
rate of those with assessments (ie, 1.3 sMMSE points for the
first 6 months and 1.1 points every 6 months subsequently).
The results from imputationmethod 1and imputationmethod
2 are shown in eFigure 2 in Supplement 2. The results are not
qualitativelydifferent fromthoseof theprimaryanalyses. The
onlyborderline significant (treatmenteffect = 1.2;95%CI,0.0-
Figure 1. Flowchart of Study
886 Patients screened
554 Patients allocated to treatment
64 Discontinued treatment
184 Assigned 400 mg
120 Completed 3 mo
19 Discontinued treatment
101 Completed 6 mo
21 Excluded
19 Discontinued treatment
2 Died (+ 1 died but
stopped trial treatment
previously)
15 Excluded because they
discontinued treatment
(+ 3 died but stopped trial
treatment previously)
27 Excluded
26 Discontinued treatment
1 Died (+ 6 died but
stopped trial treatment
previously)
80 Completed 12 mo
53 Completed 24 mo of treatment
25 Discontinued treatment
5 Discontinued treatment
181 Assigned 200 mg
156 Completed 3 mo
151 Completed 6 mo
16 Excluded
15 Discontinued treatment
1 Died
23 Excluded
22 Discontinued treatment
1 Died (+ 3 died but
stopped trial treatment
previously)
135 Completed 12 mo
112 Completed 24 mo of treatment
19 Discontinued treatment
8 Discontinued treatment
179 Assigned placebo
160 Completed 3 mo
152 Completed 6 mo
23 Excluded
18 Discontinued treatment
5 Died (+ 4 died but
stopped trial treatment
previously)
137 Completed 12 mo
114 Completed 24 mo of treatment
332 Screening failures
165 Ineligible
99 Patient or caregiver  choice
55 Unknown
13 Other reasons
10 Patients never started trial medication (1 died before month 9)
1 In 400-mg group
4 In 200-mg group
5 In placebo group
544 Patients randomized
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2.4;P = .05)differences seen in these sensitivity analyseswere
between the groups receiving 400 mg and 200 mg minocy-
clinehydrochloride.However, because the400-mggrouphad
results a little better than the placebo group and the 200-mg
group had results a little worse than the placebo group, and
no difference between any dose of minocycline and placebo,
this is likely a chance finding.
Because return rates for BADLs were also lower for the
400-mg group, we performed similar sensitivity analyses.
There were 39 participants with no BADLS assessment after
baseline who did not contribute to the primary analysis. Im-
putationmethod 1 assumed that their BADLS scoreworsened
(ie, increased) by 3.7 points during the first 6months and then
by 1.9 points every 6months for the rest of the trial.Method 2
assumed that their BADLS score worsened by 1.5 during the
first 6 months and then by 1.9 points subsequently. Because
BADLS is only valid for community-resident patients, scores
for those receiving residential carewere only imputed up un-
til the last time point before moving into a care facility. The
results for imputation methods 1 and 2 are shown in eFig-
ure 3 in Supplement 2. Again, the results were not qualita-
tivelydifferent fromthose fromtheprimaryanalysesofBADLS.
To investigate whether the efficacy of minocycline var-
ied by baseline characteristics, we did subgroup analyses of
change in sMMSE score over 24months for minocycline (any
dose) vs placebo by duration of symptoms, baseline sMMSE
score, age, and sex (eFigure 4 in Supplement 2). Therewas no
indication of any benefit from minocycline for those with
shorter or longer durationof symptoms, lower or higher base-
line sMMSE score, or formen vs women. There was a border-
line significant trend toward greater efficacy in younger pa-
tients than in older patients, but this unanticipated finding
could be a chance occurrence given the number of subgroup
investigations.
In total, there were 252 reported serious adverse events,
with themost commoncategories beingneuropsychiatric and
cardiocirculatory (Table 2). The number of serious adverse
events was somewhat higher in the placebo group (n = 105)
than the 400-mg group (n = 78) or 200-mg group (n = 69).
Given that gastrointestinal symptoms were the main reason
Table 1. Baseline Characteristics by Treatment Allocation for the 544 Eligible Patients
Characteristic
Patients No. (%)
Minocycline Hydrochloride,
400 mg (n = 184)
Minocycline Hydrochloride,
200 mg (n = 181)
Placebo
(n = 179)
Age, y
<65 22 (12.0) 22 (12.2) 21 (11.7)
65-74 68 (37.0) 66 (36.5) 66 (36.9)
≥75 94 (51.1) 93 (51.4) 92 (51.4)
Age, mean (SD), y 74.3 (8.0) 74.1 (8.4) 74.6 (8.1)
Sex
Male 104 (57) 100 (55.2) 99 (55.3)
Female 80 (43) 81 (44.8) 80 (44.7)
Race/ethnicity, No./total No.
(%)
White 173/183 (94.5) 169/176 (96.0) 171/176 (97.2)
Asian 5/183 (2.7) 1/176 (0.6) 3/176 (1.7)
Black 5/183 (2.7) 5/176 (2.8) 2/176 (1.1)
Other 0 1/176 (0.6) 0
Home circumstance
Living with spouse, partner,
or relative
153 (83.2) 153 (84.5) 149 (83.2)
Living alone 31 (16.8) 28 (15.5) 29 (16.2)
Duration of symptoms, mo
<6 20 (10.9) 20 (11.0) 20 (11.2)
≥6 164 (89.1) 161 (89.0) 159 (88.8)
Duration of symptoms, mean
(SD), mo
23.5 (18.3) 23.1 (17.8) 24.2 (18.0)
sMMSE scorea
24-26 100 (54.3) 97 (53.6) 96 (53.6)
27-30 84 (45.7) 84 (46.4) 83 (46.4)
sMMSE score, mean (SD)a 26.4 (1.9) 26.5 (1.9) 26.4 (1.8)
BADLS scoreb
0-4 100/183 (54.6) 110 (60.8) 92/178 (51.7)
5-14 70/183 (38.3) 57 (31.5) 69/178 (38.8)
≥15 13/183 (7.1) 14 (7.7) 17/178 (9.6)
BADLS score, mean (SD)b 5.6 (6.3) 4.9 (5.4) 5.5 (5.5)
Abbreviations: BADLS, Bristol
Activities of Daily Living Scale;
sMMSE, StandardisedMini-Mental
State Examination.
a Scores range from0 to 30, with
higher scores indicating better
cognitive function.
b Scores range from0 to 60, with
higher scores indicating greater
impairment.
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for stopping trial treatment, it is reassuring that the numbers
of gastrointestinal serious adverse events in the minocycline
groupswere lowandnohigher than in theplacebogroup.Simi-
larly, althoughmore skin-related toxic effects, particularlypig-
mentation, were reported with minocycline than placebo
(35.6%[130of 365] vs 21.2% [38of 179];P < .001), fewstopped
trial treatmentbecauseof such toxic effects (Table2), andonly
6skin toxiceffectswereconsideredsevere (3 receivinganydose
of minocycline and 3 receiving placebo). There were no dif-
ferences in the numbers of patients stopping treatment
because of impaired renal function, which had been a prior
concern, nor in the numbers of renal serious adverse events.
Twenty-eight patients died during the study: 10 who re-
ceived400mgofminocycline hydrochloride, 6who received
200 mg of minocycline hydrochloride, and 12 who received
placebo (eTable 3 and eFigure 5A in Supplement 2). Fifteen of
these 28 patients had stopped trial treatment prior to dying.
One additional patient died without starting trial treatment.
Rates of admission to residential care facilities were low in
this population of patients with mild AD, with no difference
in the numbers between trial groups (eFigures 5B and 5C in
Supplement 2).
Discussion
The MADE trial showed that, for patients with mild AD, 24
months ofminocycline treatment at thedoses testeddoesnot
delay the progress of cognitive or functional impairment, as
measured by the widely used sMMSE and BADLS clinical rat-
ing scales. The trial also established that minocycline hydro-
chloride at a dose of 400mg is poorly tolerated in this popu-
lation, with fewer than one-third of participants completing
24 months of treatment. By contrast, 200 mg per day of mi-
nocycline hydrochloride was well tolerated.
The failure of minocycline treatment to slow the progres-
sion of cognitive and functional decline in patients with mild
AD is disappointing given the evidence suggesting that
neuroinflammation is instrumental in AD progression7 and
given minocycline’s anti-inflammatory and neuroprotective
effects, as well as the positive data from experimental AD
models.10-16 Nonsteroidal anti-inflammatory drugs similarly
failed to slow AD progression in clinical trials,22 despite long-
term use being associated with a lower risk of developing
AD in observational studies23 and promising data from
transgenic models.24 Our findings parallel those of trials of
minocycline in other neurodegenerative disorders in which,
despite preclinical research suggesting neuroprotection,
minocycline worsened outcomes in amyotrophic lateral scle-
rosis (with faster amyotrophic lateral sclerosis functional
scale decline compared with placebo)25; had no effect in
Huntington disease,26 multiple system atrophy,27 and nega-
tive symptoms of schizophrenia28; and only short-term
benefits in multiple sclerosis.29
We consider that there could be 3 broad potential expla-
nations for thenegative resultsofour trial.First, althoughthere
is good evidence for neuroinflammation in AD,7 thismay be a
reaction topathologic characteristicsof thedisease rather than
an important factor in neurodegeneration, particularly in pa-
tients whose AD is mild. Second, even if neurodegeneration
is acceleratedbyneuroinflammation,minocyclineat thedoses
administered in the MADE trial may not have had sufficient
activity to showefficacy.Animal studies, fromwhichmuchof
the evidence for minocycline as an anti-inflammatory and
anti-AD agent come, generally used higher doses of minocy-
cline (typically equivalent to 3-7 g per day in humans),30 and
so it could be that trial participantswere not exposed to a suf-
ficiently high dose. We included the 400-mg group to inves-
tigate whether a higher dose enhanced efficacy. A study in
amyotrophic lateral sclerosis25 that escalated doses from200
to400mg reported that adverse eventswereunrelated tomi-
nocyclinedose.TheMADEtrial establishedthat treatmentwith
400 mg is poorly tolerated in patients with AD, with no ap-
parent benefit from the higher dose, despite a mean treat-
ment duration of about 1 year. Hence, efficacy ofminocycline
could not be enhanced by using higher doses.
Minocycline is potentially neuroprotective through anti-
inflammation activity (suppression of microglial prolifera-
tion and activation, reduced IL-1β and IL-6 and tumor necro-
sis factor, decreased chemokine expression, and decreased
metalloproteases), as well as antiapoptotic and antioxidant
effects.10-16 A study in traumatic brain injury found reduced
microglial activation, visualizedwith carbon 11–labeledPBR28
positron emission tomography,31 after 12 weeks of treatment
with 200 mg of minocycline hydrochloride per day, indicat-
ing that the doses in the MADE trial can have a measurable
effecton inflammation.Theassociationbetweenminocycline-
sensitive microglial activation and neurodegeneration may,
however, be complicated.Minocycline treatment in the trau-
matic brain injury study31 was also associatedwith increased
plasma neurofilament light. The faster progression seenwith
minocycline inamyotrophic lateral sclerosis25alsosuggests that
some activatedmicrogliamight have a reparative function so
Figure 2. Proportion Taking Trial Treatment Over Time
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Table 2. Incidence and Severity of Adverse Effects, Reasons for Stopping Treatment, and Serious Adverse
Events by Treatment Allocationa
Characteristic
Minocycline
Hydrochloride, 400
mg (n = 184)
Minocycline
Hydrochloride, 200
mg (n = 181)
Placebo
(n = 179)
Minocycline vs
Placebo P Value
Adverse Effects, No.
Dermatologic symptoms
(hyperpigmentation,
photosensitivity, rash)
Mild 33 38 22 .04
Moderate 27 29 13 .008
Severe 1 2 3 .37
Gastrointestinal symptoms
(diarrhea, nausea, sore mouth,
vomiting)
Mild 52 55 55 .74
Moderate 46 24 17 .004
Severe 6 1 4 .81
Neurologic symptoms (headache,
visual or auditory disturbances,
dizziness)
Mild 53 57 51 .69
Moderate 27 16 16 .32
Severe 5 6 3 .36
Infections (oral or genital
candidiasis, vaginitis, anal
irritation, bacterial enteritis,
staphylococcal, or Clostridium
difficile)
Mild 16 10 16 .46
Moderate 17 17 25 .10
Severe 4 4 7 .25
Reasons for Stopping Trial Treatment, No.
Gastrointestinal symptoms (reflux,
constipation, diarrhea,
gastroenteritis)
42 15 10 <.001
Dizziness 14 3 1 .01
Dermatologic symptoms (rash,
hyperpigmentation,
photosensitivity)
10 5 1 .02
Hematologic symptoms 5 3 1 .16
Impaired renal function 2 5 4 .81
Infection 1 2 2 .74
Shortness of breath 6 0 0 .08
Worsening dementia 1 3 3 .57
Depression or anxiety 4 2 2 .63
Joint or muscle pain 2 0 2 .47
Concomitant disease or illness 9 6 7 .91
General deterioration in physical
health
2 0 2 .47
Unknown 1 0 0 .48
Unspecified adverse effect 5 2 7 .17
Patient or carer choice 23 21 18 .49
Total 127 67 60 <.001
Serious Adverse Events, No.b
Gastrointestinal 3 8 10 .14
Respiratory 8 8 10 .54
Falls and fractures 6 11 13 .21
Endocrine and metabolic 2 1 9 .002
Cancer 12 3 11 .30
Hematologic or thrombosis 3 1 2 .98
(continued)
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that their inhibition could accelerate neurodegeneration.Our
results donot suggest thatminocyclineworsensneurodegen-
eration in AD.
A thirdplausible explanation for thenegative resultsof the
MADE trial could be thatminocycline did have some efficacy
against AD, but treatment effects were too small to be detect-
able. It is difficult to discount this possibility. TheMADE trial
was, however, powered to detect minimal clinically impor-
tant differences betweenminocycline andplacebo, so smaller
differences might not be considered of clinical relevance.
Strengths and Limitations
Our pragmatic trial had a number of strengths. It was based
within a broad network of academic and National Health Ser-
vice memory services, and the wide eligibility criteria facili-
tated the recruitment of participants, many of whom had
physical comorbidities and were representative of patients
with mild AD. Outcome measures were limited in number,
easy to administer reliably by trial staff, and chosen because
any differences between minocycline and placebo would
have unambiguous clinical relevance.
The potential limitations of the study include that bio-
markerswerenotused to confirmADdiagnosis, because these
and APOE genotyping are not routinely available within the
National Health Service. Nonetheless, no diagnoses were re-
vised by responsible clinical teams during the study, and the
rates of decline were as expected in a population of individu-
als withmild AD and comparable between themost and least
mildly impairedparticipants (eFigure 6 in Supplement 2). Ad-
herencewasalsoproblematic,with fewpatients in the400-mg
group completing 2 years of treatment andonlymoderate ad-
herence in the 200-mg and placebo groups.
Figure 3. Change inMean (SE) StandardisedMini-Mental State Examination (sMMSE) and Bristol Activities of Daily Living Scale (BADLS) Scores
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A, Change in sMMSE score from baseline to 24months. Any dose of
minocycline vs placebo: treatment effect = 0.07; 95% CI, –1.1 to 1.2; P = .90;
400mg vs 200mg: treatment effect = 1.17; 95% CI, –0.1 to 2.5; P = .08.
B, Change in BADLS score from baseline to 24months. Any dose of minocycline
vs placebo: treatment effect = –0.53; 95% CI, –2.4 to 1.3; P = .57; 400mg vs
200mg: treatment effect = –0.31; 95% CI, –0.2 to 1.8; P = .77. Baseline scores
are set to zero (baseline sMMSE scores: 26.3 in the 400-mg group, 26.5 in the
200-mg group, and 26.4 in the placebo group; baseline BADLS scores: 5.6 in
the 400-mg group, 4.9 in the 200-mg group, and 5.5 in the placebo group).
Treatment effect is the estimated difference in 2-year decline from repeated
measures analyses; P values are from tests comparing rate of decline between
groups (time by treatment interaction) from repeatedmeasures analyses.
Results from intention-to-treat analysis of 554 patients.
Table 2. Incidence and Severity of Adverse Effects, Reasons for Stopping Treatment, and Serious Adverse
Events by Treatment Allocationa (continued)
Characteristic
Minocycline
Hydrochloride, 400
mg (n = 184)
Minocycline
Hydrochloride, 200
mg (n = 181)
Placebo
(n = 179)
Minocycline vs
Placebo P Value
Dermatologic 0 1 0 .48
Stroke 4 5 12 .02
Psychiatric symptoms and seizures 6 8 4 .33
Cardiocirculatory 14 9 11 .94
Renal 3 2 2 .81
Infection 10 1 19 <.001
Other 7 11 2 .03
Total 78 69 105 <.001
a Differences were compared by χ2
test with associated 2-sided
P values.
b Serious adverse events are adverse
events that were fatal (10 in the
400-mg group, 6 in the 200-mg
group, and 12 with placebo), life
threatening, resulted in or
prolonged hospital admission, or
resulted in disability (further
information in eTable 5A and
eTable 5B in Supplement 2).
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Although the trial protocol specified that outcome
assessments should be obtained irrespective of treatment
compliance, that could not always be achieved despite the
efforts of the trial team. Consequently, differential
follow-up rates could have biased our results. However,
despite the large number of treatment withdrawals in the
400-mg group and the consequent loss to follow-up of
some participants, the results were essentially unchanged in
sensitivity analyses investigating potential bias from miss-
ing data. These analyses indicate that bias from missing
assessments would tend to underestimate decline, and
more so in the 400-mg group than in the 200-mg and pla-
cebo groups, because more assessments were missing from
the 400-mg group. We are consequently confident that
we have not missed a benefit of 400 mg of minocycline
because of missing data.
Conclusions
Twoyears ofminocycline treatment for patientswithmildAD
does not result in any clinically meaningful difference in the
rate of decline of cognitive and functional ability. This find-
ing is disappointing but robust.
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Additional Information: The Collaborative Group
members Dr Jones andMs Paul died unexpectedly
during the course of theMADE trial.
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